Logan Capital Management Inc. maintained its stake in Stryker Corporation (NYSE:SYK) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,500 shares of the medical technology company’s stock at the end of the first quarter. Logan Capital Management Inc.’s holdings in Stryker Corporation were worth $461,000 as of its most recent filing with the SEC.
A number of other large investors have also recently bought and sold shares of the stock. Schwab Charles Investment Management Inc. boosted its stake in Stryker Corporation by 4.2% in the first quarter. Schwab Charles Investment Management Inc. now owns 964,327 shares of the medical technology company’s stock worth $126,954,000 after buying an additional 38,772 shares during the last quarter. Dynamic Capital Management Ltd bought a new position in Stryker Corporation during the first quarter worth about $624,000. KCG Holdings Inc. boosted its position in Stryker Corporation by 12.5% in the first quarter. KCG Holdings Inc. now owns 9,163 shares of the medical technology company’s stock worth $1,206,000 after buying an additional 1,019 shares in the last quarter. BlackRock Inc. boosted its position in Stryker Corporation by 2,526.4% in the first quarter. BlackRock Inc. now owns 21,976,771 shares of the medical technology company’s stock worth $2,893,242,000 after buying an additional 21,140,000 shares in the last quarter. Finally, Renaissance Technologies LLC bought a new position in Stryker Corporation during the first quarter worth about $948,000. 73.99% of the stock is owned by institutional investors.
Stryker Corporation (NYSE:SYK) traded up 0.19% during mid-day trading on Friday, reaching $144.18. 847,631 shares of the company traded hands. The stock’s 50 day moving average price is $143.71 and its 200 day moving average price is $135.51. Stryker Corporation has a 52 week low of $106.48 and a 52 week high of $148.84. The firm has a market capitalization of $53.93 billion, a price-to-earnings ratio of 32.18 and a beta of 0.80.
Stryker Corporation (NYSE:SYK) last announced its quarterly earnings data on Thursday, July 27th. The medical technology company reported $1.53 EPS for the quarter, topping the Zacks’ consensus estimate of $1.51 by $0.02. The company had revenue of $3.01 billion during the quarter, compared to the consensus estimate of $2.98 billion. Stryker Corporation had a net margin of 14.22% and a return on equity of 24.26%. Stryker Corporation’s quarterly revenue was up 6.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.39 EPS. Equities analysts forecast that Stryker Corporation will post $6.50 EPS for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, October 31st. Shareholders of record on Friday, September 29th will be given a dividend of $0.425 per share. The ex-dividend date is Thursday, September 28th. This represents a $1.70 dividend on an annualized basis and a yield of 1.18%. Stryker Corporation’s payout ratio is currently 37.95%.
WARNING: This piece was originally published by BNB Daily and is owned by of BNB Daily. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The correct version of this piece can be read at https://www.baseball-news-blog.com/2017/08/13/stryker-corporation-nysesyk-position-maintained-by-logan-capital-management-inc-updated.html.
A number of research analysts have issued reports on SYK shares. Deutsche Bank AG reaffirmed a “buy” rating and issued a $148.00 price target (up previously from $135.00) on shares of Stryker Corporation in a report on Saturday, April 29th. BidaskClub cut shares of Stryker Corporation from a “strong-buy” rating to a “buy” rating in a report on Tuesday, June 13th. Zacks Investment Research raised shares of Stryker Corporation from a “hold” rating to a “buy” rating and set a $163.00 price target for the company in a report on Monday, July 17th. Stifel Nicolaus raised their price target on shares of Stryker Corporation from $151.00 to $158.00 and gave the stock a “buy” rating in a report on Friday, July 28th. Finally, Cowen and Company reaffirmed a “buy” rating and issued a $160.00 price target (up previously from $150.00) on shares of Stryker Corporation in a report on Sunday, July 30th. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and twelve have assigned a buy rating to the company. Stryker Corporation presently has a consensus rating of “Hold” and a consensus price target of $144.03.
In other Stryker Corporation news, insider David Floyd sold 19,305 shares of the company’s stock in a transaction on Wednesday, July 12th. The shares were sold at an average price of $144.56, for a total transaction of $2,790,730.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Lonny J. Carpenter sold 5,000 shares of the company’s stock in a transaction on Friday, August 4th. The stock was sold at an average price of $146.36, for a total transaction of $731,800.00. Following the transaction, the insider now directly owns 88,207 shares in the company, valued at $12,909,976.52. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 32,810 shares of company stock valued at $4,754,958. 7.40% of the stock is owned by insiders.
About Stryker Corporation
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.
Receive News & Ratings for Stryker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corporation and related companies with MarketBeat.com's FREE daily email newsletter.